Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 16

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Inherited Predispositions to Myeloid Neoplasms: Pathogenesis and Clinical Implications

Liu, Yen-Chun, Eldomery, Mohammad K., Maciaszek, Jamie L., Klco, Jeffery M.·2025·Annual Review of Pathology: Mechanisms of Disease

Abstract

Myeloid neoplasms with and without preexisting platelet disorders frequently develop in association with an underlying germline predisposition. Germline alterations affecting ANKRD26 , CEBPA , DDX41 , ETV6 , and RUNX1 are associated with nonsyndromic predisposition to the development of myeloid neoplasms including acute myeloid leukemia and myelodysplastic syndrome. However, germline predisposition to myeloid neoplasms is also associated with a wide range of other syndromes, including SAMD9 / 9L associated predisposition, GATA2 deficiency, RASopathies, ribosomopathies, telomere biology disorders, Fanconi anemia, severe congenital neutropenia, Down syndrome, and others. In the fifth edition of the World Health Organization (WHO) series on the classification of tumors of hematopoietic and lymphoid tissues, myeloid neoplasms associated with germline predisposition have been recognized as a separate entity. Here, we review several disorders from this WHO entity as well as other related conditions with an emphasis on the molecular pathogenesis of disease and accompanying somatic alterations. Finally, we provide an overview of establishing the molecular diagnosis of these germline genetic conditions and general recommendations for screening and management of the associated hematologic conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1146/annurev-pathmechdis-111523-023420

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 203

  1. 2017, RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM), Semin. Hematol., 54, 75, 10.1053/j.seminhematol.2017.04.006 · DOI
  2. 2023, Hereditary platelet disorders associated with germ line variants in RUNX1, ETV6, and ANKRD26, Blood, 141, 1533, 10.1182/blood.2022017735 · DOI
  3. 2020, RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML, Blood Adv, 4, 1131, 10.1182/bloodadvances.2019000901 · DOI · Paper page
  4. 2020, High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML, Blood, 135, 1882, 10.1182/blood.2019003357 · DOI
  5. 2021, RUNX1 germline variants in RUNX1-mutant AML: how frequent?, Blood, 137, 1428, 10.1182/blood.2020008478 · doi:10.1182/blood.2020008478
  6. 2016, RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features, Leukemia, 30, 2160, 10.1038/leu.2016.126 · DOI · Paper page
  7. 2012, RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures, J. Clin. Oncol., 30, 3109, 10.1200/JCO.2011.40.6652 · DOI · Paper page
  8. 2024, Haematolymphoid Tumours, Part A, 11
  9. 2023, A critical role of RUNX1 in governing megakaryocyte-primed hematopoietic stem cell differentiation, Blood Adv, 7, 2590, 10.1182/bloodadvances.2022008591 · DOI
  10. 2010, Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis, Blood, 115, 1610, 10.1182/blood-2009-07-232249 · DOI
  11. 2007, Isoform-specific potentiation of stem and progenitor cell engraftment by AML1/RUNX1, PLOS Med, 4, e172, 10.1371/journal.pmed.0040172 · DOI
  12. 2011, Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families, Blood, 117, 6673, 10.1182/blood-2011-02-336537 · DOI · Paper page
  13. 2011, Mutations in the 5′ UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2, Am. J. Hum. Genet., 88, 115, 10.1016/j.ajhg.2010.12.006 · DOI · Paper page
  14. 2013, ANKRD26-related thrombocytopenia and myeloid malignancies, Blood, 122, 1987, 10.1182/blood-2013-04-499319 · DOI · Paper page
  15. 2014, Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation, J. Clin. Investig., 124, 580, 10.1172/JCI71861 · DOI · Paper page
  16. 2015, Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia, Nat. Genet., 47, 535, 10.1038/ng.3253 · DOI · Paper page
  17. 2015, Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy, Nat. Genet., 47, 180, 10.1038/ng.3177 · DOI · Paper page
  18. 2021, Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia, Blood, 137, 364, 10.1182/blood.2020006164 · DOI
  19. 2001, TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3, Oncogene, 20, 3716, 10.1038/sj.onc.1204479 · DOI · Paper page
  20. 1998, The ets family member Tel binds to the Fli-1 oncoprotein and inhibits its transcriptional activity, J. Biol. Chem., 273, 17525, 10.1074/jbc.273.28.17525 · DOI
  21. 2004, Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival, Genes Dev, 18, 2336, 10.1101/gad.1239604 · DOI · Paper page
  22. 1998, The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow, Genes Dev, 12, 2392, 10.1101/gad.12.15.2392 · DOI · Paper page
  23. 2022, ETV6-related thrombocytopenia: dominant negative effect of mutations as common pathogenic mechanism, Haematologica, 107, 2249, 10.3324/haematol.2022.280729 · DOI
  24. 2015, Disease evolution and outcomes in familial AML with germline CEBPA mutations, Blood, 126, 1214, 10.1182/blood-2015-05-647172 · DOI · Paper page
  25. 2016, Whole exome sequencing reveals a C-terminal germline variant in CEBPA-associated acute myeloid leukemia: 45-year follow up of a large family, Haematologica, 101, 846, 10.3324/haematol.2015.130799 · DOI
  26. 2009, Complexity of CEBPA dysregulation in human acute myeloid leukemia, Clin. Cancer Res., 15, 5303, 10.1158/1078-0432.CCR-08-2941 · DOI
  27. 2017, Expression and regulation of C/EBPα in normal myelopoiesis and in malignant transformation, Blood, 129, 2083, 10.1182/blood-2016-09-687822 · DOI · Paper page
  28. 2014, Granulopoiesis requires increased C/EBPα compared to monopoiesis, correlated with elevated Cebpa in immature G-CSF receptor versus M-CSF receptor expressing cells, PLOS ONE, 9, e95784, 10.1371/journal.pone.0095784 · DOI
  29. 2014, CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation, Sci. Rep., 4, 4261, 10.1038/srep04261 · DOI
  30. 1993, CCAAT/enhancer-binding protein mRNA is translated into multiple proteins with different transcription activation potentials, PNAS, 90, 8219, 10.1073/pnas.90.17.8219 · DOI · Paper page
  31. 1994, Translation start site multiplicity of the CCAAT/enhancer binding protein α mRNA is dictated by a small 5′ open reading frame, Nucleic Acids Res, 22, 5540, 10.1093/nar/22.25.5540 · DOI
  32. 1996, Evidence for posttranscriptional regulation of C/EBPα and C/EBPβ isoform expression during the lipopolysaccharide-mediated acute-phase response, Mol. Cell. Biol., 16, 2295, 10.1128/MCB.16.5.2295 · DOI
  33. 2023, Germ line DDX41 mutations define a unique subtype of myeloid neoplasms, Blood, 141, 534, 10.1182/blood.2022018221 · DOI
  34. 2015, Inherited and somatic defects in DDX41 in myeloid neoplasms, Cancer Cell, 27, 658, 10.1016/j.ccell.2015.03.017 · DOI · Paper page
  35. 2023, The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia, Virchows Arch, 482, 113, 10.1007/s00428-022-03447-9 · DOI
  36. 2022, AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome, Leukemia, 36, 664, 10.1038/s41375-021-01404-0 · DOI
  37. 2023, DDX41-associated susceptibility to myeloid neoplasms, Blood, 141, 1544, 10.1182/blood.2022017715 · DOI
  38. 2021, Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia, Cell Stem Cell, 28, 1966, 10.1016/j.stem.2021.08.004 · DOI
  39. 2015, Bruton's tyrosine kinase phosphorylates DDX41 and activates its binding of dsDNA and STING to initiate type 1 interferon response, Cell Rep, 10, 1055, 10.1016/j.celrep.2015.01.039 · DOI
  40. 2023, Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies, Blood Adv, 7, 549, 10.1182/bloodadvances.2022008172 · DOI
  41. 2022, Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia, Bone Marrow Transplant, 57, 1716, 10.1038/s41409-022-01776-6 · doi:10.1038/s41409-022-01776-6
  42. 2015, The genomic landscape of juvenile myelomonocytic leukemia, Nat. Genet., 47, 1326, 10.1038/ng.3400 · DOI · Paper page
  43. 2005, The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease, Blood, 106, 2183, 10.1182/blood-2005-02-0531 · DOI · Paper page
  44. 2022, The RASopathies: biology, genetics and therapeutic options, Adv. Cancer Res., 153, 305, 10.1016/bs.acr.2021.07.007 · DOI
  45. 2010, Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia, Nat. Genet., 42, 794, 10.1038/ng.641 · DOI · Paper page
  46. 2010, Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004–2006, Birth Defects Res. A Clin. Mol. Teratol., 88, 1008, 10.1002/bdra.20735 · DOI · Paper page
  47. 2000, Risks of leukaemia and solid tumours in individuals with Down's syndrome, Lancet, 355, 165, 10.1016/S0140-6736(99)05264-2 · DOI · Paper page
  48. 2007, Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome, Blood, 110, 2128, 10.1182/blood-2007-01-069542 · DOI
  49. 2014, Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group, Blood, 123, 70, 10.1182/blood-2013-06-509463 · DOI · Paper page
  50. 2008, Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome, Lancet, 372, 1484, 10.1016/S0140-6736(08)61341-0 · DOI · Paper page
  51. 2010, Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group, Blood, 115, 1006, 10.1182/blood-2009-08-235408 · DOI · Paper page
  52. 2021, Leukemia risk in a cohort of 3.9 million children with and without Down syndrome, J. Pediatr., 234, 172, 10.1016/j.jpeds.2021.03.001 · DOI
  53. 2008, Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations, Blood, 112, 4507, 10.1182/blood-2008-04-152967 · DOI · Paper page
  54. 2002, Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome, Nat. Genet., 32, 148, 10.1038/ng955 · DOI · Paper page
  55. 2022, Advances in molecular characterization of myeloid proliferations associated with Down syndrome, Front. Genet., 13, 891214, 10.3389/fgene.2022.891214 · DOI
  56. 2023, RUNX1 isoform disequilibrium promotes the development of trisomy 21-associated myeloid leukemia, Blood, 141, 1105, 10.1182/blood.2022017619 · DOI
  57. 1954, Congenital telangiectatic erythema resembling lupus erythematosus in dwarfs; probably a syndrome entity, AMA Am. J. Dis. Child, 88, 754
  58. 1974, Bloom's syndrome. III. Analysis of the chromosome aberration characteristic of this disorder, Chromosoma, 48, 361, 10.1007/BF00290993 · DOI
  59. 1977, Bloom's syndrome. IV. Sister-chromatid exchanges in lymphocytes, Am. J. Hum. Genet., 29, 248
  60. 2014, Human RecQ helicases in DNA repair, recombination, and replication, Annu. Rev. Biochem., 83, 519, 10.1146/annurev-biochem-060713-035428 · DOI · Paper page
  61. 2000, Association of the Bloom syndrome protein with topoisomerase IIIα in somatic and meiotic cells, Cancer Res, 60, 1162
  62. 2021, Bloom syndrome DNA helicase deficiency is associated with oxidative stress and mitochondrial network changes, Sci. Rep., 11, 2157, 10.1038/s41598-021-81075-0 · DOI
  63. 1998, Carrier frequency of the Bloom syndrome blm Ash mutation in the Ashkenazi Jewish population, Mol. Genet. Metab., 64, 286, 10.1006/mgme.1998.2733 · DOI
  64. 2011, Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome, Blood, 118, 2653, 10.1182/blood-2011-05-356352 · DOI · Paper page
  65. 2011, Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency, Blood, 118, 2656, 10.1182/blood-2011-06-360313 · DOI · Paper page
  66. 2011, Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia, Nat. Genet., 43, 1012, 10.1038/ng.913 · DOI · Paper page
  67. 2011, Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome), Nat. Genet., 43, 929, 10.1038/ng.923 · DOI · Paper page
  68. 2013, High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia, Blood, 121, 822, 10.1182/blood-2012-08-447367 · DOI · Paper page
  69. 2018, A landscape of germ line mutations in a cohort of inherited bone marrow failure patients, Blood, 131, 717, 10.1182/blood-2017-09-806489 · DOI · Paper page
  70. 2018, Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients, Haematologica, 103, 1278, 10.3324/haematol.2017.181909 · DOI · Paper page
  71. 2016, Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents, Blood, 127, 1387, 10.1182/blood-2015-09-669937 · DOI · Paper page
  72. 2023, Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41, Blood Adv, 7, 6092, 10.1182/bloodadvances.2023010045 · DOI
  73. 2011, Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications, Haematologica, 96, 1221, 10.3324/haematol.2011.041152 · DOI
  74. 2015, GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia, Blood, 125, 56, 10.1182/blood-2014-06-580340 · DOI · Paper page
  75. 1992, GATA-binding transcription factors in hematopoietic cells, Blood, 80, 575, 10.1182/blood.V80.3.575.575 · DOI · Paper page
  76. 2013, Gata2 cis-element is required for hematopoietic stem cell generation in the mammalian embryo, J. Exp. Med., 210, 2833, 10.1084/jem.20130733 · DOI
  77. 1994, An early haematopoietic defect in mice lacking the transcription factor GATA-2, Nature, 371, 221, 10.1038/371221a0 · DOI · Paper page
  78. 2005, Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis, Blood, 106, 477, 10.1182/blood-2004-08-2989 · DOI · Paper page
  79. 2004, GATA-2 plays two functionally distinct roles during the ontogeny of hematopoietic stem cells, J. Exp. Med., 200, 871, 10.1084/jem.20031556 · DOI · Paper page
  80. 2020, Human GATA2 mutations and hematologic disease: how many paths to pathogenesis?, Blood Adv, 4, 4584, 10.1182/bloodadvances.2020002953 · DOI
  81. 2016, SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7, Nat. Genet., 48, 792, 10.1038/ng.3569 · DOI · Paper page
  82. 2016, Ataxia-pancytopenia syndrome is caused by missense mutations in SAMD9L, Am. J. Hum. Genet., 98, 1146, 10.1016/j.ajhg.2016.04.009 · DOI · Paper page
  83. 2017, Germline SAMD9 mutation in siblings with monosomy 7 and myelodysplastic syndrome, Leukemia, 31, 1827, 10.1038/leu.2017.142 · doi:10.1038/leu.2017.142
  84. 2017, The genomic landscape of pediatric myelodysplastic syndromes, Nat. Commun., 8, 1557, 10.1038/s41467-017-01590-5 · DOI · Paper page
  85. 2018, Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes, JCI Insight, 3, e121086, 10.1172/jci.insight.121086 · DOI
  86. 2021, Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes, Nat. Med., 27, 1806, 10.1038/s41591-021-01511-6 · DOI · Paper page
  87. 2018, Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes, Blood, 132, 2309, 10.1182/blood-2017-05-787390 · DOI
  88. 2020, Germline predisposition in myeloid neoplasms: unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes, Best Pract. Res. Clin. Haematol., 33, 101197, 10.1016/j.beha.2020.101197 · DOI
  89. 2021, Pediatric MDS and bone marrow failure-associated germline mutations in SAMD9 and SAMD9L impair multiple pathways in primary hematopoietic cells, Leukemia, 35, 3232, 10.1038/s41375-021-01212-6 · DOI
  90. 2017, Somatic mutations and progressive monosomy modify SAMD9-related phenotypes in humans, J. Clin. Investig., 127, 1700, 10.1172/JCI91913 · DOI · Paper page
  91. 2022, Mutant Samd9l expression impairs hematopoiesis and induces bone marrow failure in mice, J. Clin. Investig., 132, e158869, 10.1172/JCI158869 · DOI
  92. 2023, Human SAMD9 is a poxvirus-activatable anticodon nuclease inhibiting codon-specific protein synthesis, Sci. Adv., 9, eadh8502, 10.1126/sciadv.adh8502 · DOI
  93. 2019, An update on the biology and management of dyskeratosis congenita and related telomere biology disorders, Expert Rev. Hematol., 12, 1037, 10.1080/17474086.2019.1662720 · DOI · Paper page
  94. 1993, Dyskeratosis congenita and related telomere biology disorders
  95. 2017, Classical inherited bone marrow failure syndromes with high risk for myelodysplastic syndrome and acute myelogenous leukemia, Semin. Hematol., 54, 105, 10.1053/j.seminhematol.2017.04.004 · DOI
  96. 2023, Clinical manifestations of telomere biology disorders in adults, Hematol. Am. Soc. Hematol. Educ. Progr., 2023, 563, 10.1182/hematology.2023000490 · DOI
  97. 2012, Dyskeratosis congenita as a disorder of telomere maintenance, Mutat. Res., 730, 43
  98. 2011, Dyskeratosis congenita, Hematol. Am. Soc. Hematol. Educ. Progr., 2011, 480, 10.1182/asheducation-2011.1.480 · DOI · Paper page
  99. 2018, Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up, Haematologica, 103, 30, 10.3324/haematol.2017.178111 · DOI · Paper page
  100. 2015, Clinical utility gene card for: Dyskeratosis congenita – update 2015, Eur. J. Hum. Genet., 23, 558
  101. 2007, Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita, Blood, 110, 1439, 10.1182/blood-2007-02-075598 · DOI · Paper page
  102. 2012, Telomere length is associated with disease severity and declines with age in dyskeratosis congenita, Haematologica, 97, 353, 10.3324/haematol.2011.055269 · DOI · Paper page
  103. 2017, Telomeres in cancer: tumour suppression and genome instability, Nat. Rev. Mol. Cell Biol., 18, 175, 10.1038/nrm.2016.171 · DOI · Paper page
  104. 2021, Shaping human telomeres: from shelterin and CST complexes to telomeric chromatin organization, Nat. Rev. Mol. Cell Biol., 22, 283, 10.1038/s41580-021-00328-y · DOI · Paper page
  105. 2009, How telomeres solve the end-protection problem, Science, 326, 948, 10.1126/science.1170633 · DOI · Paper page
  106. 2023, Genetics of human telomere biology disorders, Nat. Rev. Genet., 24, 86, 10.1038/s41576-022-00527-z · DOI · Paper page
  107. 2014, In the end, what's the problem?, Mol. Cell, 53, 855, 10.1016/j.molcel.2014.03.008 · DOI
  108. 2022, Telomere-mediated lung disease, Physiol. Rev., 102, 1703, 10.1152/physrev.00046.2021 · DOI · Paper page
  109. 2022, Consequences of telomere replication failure: the other end-replication problem, Trends Biochem. Sci., 47, 506, 10.1016/j.tibs.2022.03.013 · DOI
  110. 2012, Removal of shelterin reveals the telomere end-protection problem, Science, 336, 593, 10.1126/science.1218498 · DOI · Paper page
  111. 2016, Understanding TERT promoter mutations: a common path to immortality, Mol. Cancer Res., 14, 315, 10.1158/1541-7786.MCR-16-0003 · DOI · Paper page
  112. 2021, Telomeres and cancer, Life, 11, 1405, 10.3390/life11121405 · DOI
  113. 1995, Telomere elongation in immortal human cells without detectable telomerase activity, EMBO J, 14, 4240, 10.1002/j.1460-2075.1995.tb00098.x · DOI · Paper page
  114. 2021, Structure of human telomerase holoenzyme with bound telomeric DNA, Nature, 593, 449, 10.1038/s41586-021-03415-4 · DOI · Paper page
  115. 1994, Specific association of human telomerase activity with immortal cells and cancer, Science, 266, 2011, 10.1126/science.7605428 · DOI · Paper page
  116. 2011, The role of telomeres in the ageing of human skin, Exp. Dermatol., 20, 297, 10.1111/j.1600-0625.2010.01242.x · DOI · Paper page
  117. 1996, Telomerase activity in human intestine, Int. J. Oncol., 9, 453
  118. 2016, Inhibition of telomerase RNA decay rescues telomerase deficiency caused by dyskerin or PARN defects, Nat. Struct. Mol. Biol., 23, 286, 10.1038/nsmb.3184 · DOI
  119. 2006, hNaf1 is required for accumulation of human box H/ACA snoRNPs, scaRNPs, and telomerase, RNA, 12, 832, 10.1261/rna.2344106 · DOI
  120. 2016, Loss-of-function mutations in the RNA biogenesis factor NAF1 predispose to pulmonary fibrosis-emphysema, Sci. Transl. Med., 8, 351ra107
  121. 2015, A polyadenylation-dependent 3′ end maturation pathway is required for the synthesis of the human telomerase RNA, Cell Rep, 13, 2244, 10.1016/j.celrep.2015.11.003 · DOI
  122. 2019, ZCCHC8, the nuclear exosome targeting component, is mutated in familial pulmonary fibrosis and is required for telomerase RNA maturation, Genes Dev, 33, 1381, 10.1101/gad.326785.119 · DOI
  123. 2021, Shaping human telomeres: from shelterin and CST complexes to telomeric chromatin organization, Nat. Rev. Mol. Cell Biol., 22, 283, 10.1038/s41580-021-00328-y · DOI · Paper page
  124. 2020, TINF2 is a haploinsufficient tumor suppressor that limits telomere length, eLife, 9, e61235, 10.7554/eLife.61235 · DOI
  125. 2014, Inherited bone marrow failure associated with germline mutation of ACD, the gene encoding telomere protein TPP1, Blood, 124, 2767, 10.1182/blood-2014-08-596445 · DOI
  126. 2015, Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma, J. Natl. Cancer Inst., 107, dju408
  127. 2016, Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia, Blood, 128, 2319, 10.1182/blood-2016-01-695692 · DOI
  128. 2013, POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia, Nat. Genet., 45, 526, 10.1038/ng.2584 · DOI · Paper page
  129. 2017, The wide spectrum of POT1 gene variants correlates with multiple cancer types, Eur. J. Hum. Genet., 25, 1278, 10.1038/ejhg.2017.134 · DOI
  130. 2016, A POT1 mutation implicates defective telomere end fill-in and telomere truncations in Coats plus, Genes Dev, 30, 812, 10.1101/gad.276873.115 · DOI
  131. 1993, Fanconi anemia
  132. 2012, Molecular pathogenesis and clinical management of Fanconi anemia, J. Clin. Investig., 122, 3799, 10.1172/JCI58321 · DOI · Paper page
  133. 2019, The Fanconi anemia pathway in cancer, Annu. Rev. Cancer Biol., 3, 457, 10.1146/annurev-cancerbio-030617-050422 · DOI · Paper page
  134. 2024, Fanconi anemia
  135. 2021, An update on Fanconi anemia: clinical, cytogenetic and molecular approaches (review), Biomed. Rep., 15, 74, 10.3892/br.2021.1450 · doi:10.3892/br.2021.1450
  136. 2010, Pathophysiology and management of inherited bone marrow failure syndromes, Blood Rev, 24, 101, 10.1016/j.blre.2010.03.002 · DOI · Paper page
  137. 2009, Fanconi anemia and its diagnosis, Mutat. Res., 668, 4
  138. 2016, How I treat MDS and AML in Fanconi anemia, Blood, 127, 2971, 10.1182/blood-2016-01-583625 · DOI
  139. 1994, Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study, Blood, 84, 1650, 10.1182/blood.V84.5.1650.1650 · DOI · Paper page
  140. 1983, L'anémie de Fanconi. Fréquence de l'évolution vers la leucémie. [Fanconi's anemia. Incidence of its development into leukemia, Presse Med, 12, 1269
  141. 1996, Prolonged administration of granulocyte colony-stimulating factor (filgrastim) to patients with Fanconi anemia: a pilot study, Blood, 88, 1588, 10.1182/blood.V88.5.1588.1588 · DOI · Paper page
  142. 2003, Cancer incidence in persons with Fanconi anemia, Blood, 101, 822, 10.1182/blood-2002-05-1498 · DOI · Paper page
  143. 2003, Cancer in Fanconi anemia, Blood, 101, 2072, 10.1182/blood-2002-11-3597 · DOI · Paper page
  144. 2008, Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry, Haematologica, 93, 511, 10.3324/haematol.12234 · DOI · Paper page
  145. 2003, Cancer in Fanconi anemia, 1927–2001, Cancer, 97, 425, 10.1002/cncr.11046 · DOI · Paper page
  146. 2010, Diagnosis of myelodysplastic syndrome among a cohort of 119 patients with fanconi anemia: morphologic and cytogenetic characteristics, Am. J. Clin. Pathol., 133, 92, 10.1309/AJCP7W9VMJENZOVG · DOI
  147. 2011, Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions, Blood, 117, e161, 10.1182/blood-2010-09-308726 · DOI · Paper page
  148. 2016, The Fanconi anaemia pathway: new players and new functions, Nat. Rev. Mol. Cell Biol., 17, 337, 10.1038/nrm.2016.48 · DOI · Paper page
  149. 2013, DNA crosslinking damage and cancer—a tale of friend and foe, Transl. Cancer Res., 2, 144
  150. 2012, Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells, Cell Stem Cell, 11, 36, 10.1016/j.stem.2012.05.013 · DOI · Paper page
  151. 2012, Damage control and its costs: BM failure in Fanconi anemia stems from overactive p53/p21, Cell Stem Cell, 11, 7, 10.1016/j.stem.2012.06.013 · doi:10.1016/j.stem.2012.06.013
  152. 2010, The FANCM/FAAP24 complex is required for the DNA interstrand crosslink-induced checkpoint response, Mol. Cell, 39, 259, 10.1016/j.molcel.2010.07.005 · DOI
  153. 2003, A novel ubiquitin ligase is deficient in Fanconi anemia, Nat. Genet., 35, 165, 10.1038/ng1241 · DOI · Paper page
  154. 2015, Deficiency of UBE2T, the E2 ubiquitin ligase necessary for FANCD2 and FANCI ubiquitination, causes FA-T subtype of Fanconi anemia, Cell Rep, 12, 35, 10.1016/j.celrep.2015.06.014 · DOI
  155. 2007, A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway, Mol. Cell, 28, 786, 10.1016/j.molcel.2007.09.031 · DOI · Paper page
  156. 2011, Mutations of the SLX4 gene in Fanconi anemia, Nat. Genet., 43, 142, 10.1038/ng.750 · DOI · Paper page
  157. 2011, SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype, Nat. Genet., 43, 138, 10.1038/ng.751 · DOI · Paper page
  158. 2009, Human SLX4 is a Holliday junction resolvase subunit that binds multiple DNA repair/recombination endonucleases, Cell, 138, 78, 10.1016/j.cell.2009.06.029 · DOI · Paper page
  159. 2008, Mechanism of replication-coupled DNA interstrand crosslink repair, Cell, 134, 969, 10.1016/j.cell.2008.08.030 · DOI · Paper page
  160. 2016, Involvement of translesion synthesis DNA polymerases in DNA interstrand crosslink repair, DNA Repair, 44, 33, 10.1016/j.dnarep.2016.05.004 · DOI
  161. 2009, How the Fanconi anemia pathway guards the genome, Annu. Rev. Genet., 43, 223, 10.1146/annurev-genet-102108-134222 · DOI · Paper page
  162. 2016, Interplay between Fanconi anemia and homologous recombination pathways in genome integrity, EMBO J, 35, 909, 10.15252/embj.201693860 · DOI · Paper page
  163. 2019, Ribosomopathies: old concepts, new controversies, Trends Genet, 35, 754, 10.1016/j.tig.2019.07.004 · DOI · Paper page
  164. 2023, Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances, Blood, 141, 1513, 10.1182/blood.2022017739 · DOI
  165. 2014, Ribosomopathies: mechanisms of disease, Clin. Med. Insights Blood Disord., 7, 7
  166. 2008, Identification of RPS14 as a 5q− syndrome gene by RNA interference screen, Nature, 451, 335, 10.1038/nature06494 · DOI · Paper page
  167. 2021, Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy, Signal Transduct. Target. Ther., 6, 323, 10.1038/s41392-021-00728-8 · DOI · Paper page
  168. 2019, Rare ribosomopathies: insights into mechanisms of cancer, Nat. Rev. Cancer, 19, 228, 10.1038/s41568-019-0105-0 · DOI
  169. 1988, Multicopy plasmid stability in Escherichia coli requires host-encoded functions that lead to plasmid site-specific recombination, Mol. Gen. Genet., 214, 80, 10.1007/BF00340183 · DOI
  170. 2017, Ribosomopathies: There's strength in numbers, Science, 358, eaan2755, 10.1126/science.aan2755 · DOI · Paper page
  171. 2012, Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress, PNAS, 109, 20467, 10.1073/pnas.1218535109 · DOI · Paper page
  172. 2018, Molecular basis of the human ribosomopathy Shwachman-Diamond syndrome, Adv. Biol. Regul., 67, 109, 10.1016/j.jbior.2017.09.002 · DOI · Paper page
  173. 2016, DNAJC21 mutations link a cancer-prone bone marrow failure syndrome to corruption in 60S ribosome subunit maturation, Am. J. Hum. Genet., 99, 115, 10.1016/j.ajhg.2016.05.002 · DOI
  174. 2017, Biallelic mutations in DNAJC21 cause Shwachman-Diamond syndrome, Blood, 129, 1557, 10.1182/blood-2016-08-735431 · doi:10.1182/blood-2016-08-735431
  175. 2019, EFL1 mutations impair eIF6 release to cause Shwachman-Diamond syndrome, Blood, 134, 277, 10.1182/blood.2018893404 · DOI
  176. 2021, SRP54 mutations induce congenital neutropenia via dominant-negative effects on XBP1 splicing, Blood, 137, 1340, 10.1182/blood.2020008115 · DOI
  177. 2017, Mutations in signal recognition particle SRP54 cause syndromic neutropenia with Shwachman-Diamond-like features, J. Clin. Investig., 127, 4090, 10.1172/JCI92876 · DOI · Paper page
  178. 1993, Diamond-Blackfan anemia
  179. 2014, Altered translation of GATA1 in Diamond-Blackfan anemia, Nat. Med., 20, 748, 10.1038/nm.3557 · DOI · Paper page
  180. 2014, Diamond-Blackfan anemia with mandibulofacial dystostosis is heterogeneous, including the novel DBA genes TSR2 and RPS28, Am. J. Med. Genet. A, 164A, 2240
  181. 2017, Severe congenital neutropenias, Nat. Rev. Dis. Primers, 3, 17032, 10.1038/nrdp.2017.32 · DOI · Paper page
  182. 2013, Epidemiology of congenital neutropenia, Hematol. Oncol. Clin. North Am., 27, 1
  183. 2012, Incidence of severe congenital neutropenia in Sweden and risk of evolution to myelodysplastic syndrome/leukaemia, Br. J. Haematol., 158, 363, 10.1111/j.1365-2141.2012.09171.x · doi:10.1111/j.1365-2141.2012.09171.x
  184. 2006, The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy, Blood, 107, 4628, 10.1182/blood-2005-11-4370 · DOI · Paper page
  185. 1995, Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia, N. Engl. J. Med., 333, 487, 10.1056/NEJM199508243330804 · DOI · Paper page
  186. 2007, Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey, Blood, 109, 93, 10.1182/blood-2006-02-004275 · DOI · Paper page
  187. 2007, Neutrophil elastase in cyclic and severe congenital neutropenia, Blood, 109, 1817, 10.1182/blood-2006-08-019166 · DOI · Paper page
  188. 2003, Cellular and molecular abnormalities in severe congenital neutropenia predisposing to leukemia, Exp. Hematol., 31, 372, 10.1016/S0301-472X(03)00048-1 · doi:10.1016/s0301-472x(03)00048-1
  189. 2007, HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease), Nat. Genet., 39, 86, 10.1038/ng1940 · DOI · Paper page
  190. 2022, Heterozygous variants of CLPB are a cause of severe congenital neutropenia, Blood, 139, 779, 10.1182/blood.2021010762 · DOI
  191. 2015, Germline mutations in predisposition genes in pediatric cancer. New Engl, J. Med., 373, 2336
  192. 2021, Genomes for kids: the scope of pathogenic mutations in pediatric cancer revealed by comprehensive DNA and RNA sequencing, Cancer Discov, 11, 3008, 10.1158/2159-8290.CD-20-1631 · DOI · Paper page
  193. 2023, Prioritization of patients for germline testing based on tumor profiling of hematopoietic malignancies, Front. Oncol., 13, 1084736, 10.3389/fonc.2023.1084736 · DOI
  194. 2020, What's germane in the germline? Finding clinically relevant germline variants in myeloid neoplasms from tumor only screening, Leuk. Res., 96, 106431, 10.1016/j.leukres.2020.106431 · DOI
  195. 2021, Inherited susceptibility to hematopoietic malignancies in the era of precision oncology, JCO Precis. Oncol., 5, 107
  196. 2014, Bone marrow failure and the telomeropathies, Blood, 124, 2775, 10.1182/blood-2014-05-526285 · DOI · Paper page
  197. 2018, Fanconi anaemia and cancer: an intricate relationship, Nat. Rev. Cancer, 18, 168, 10.1038/nrc.2017.116 · DOI · Paper page
  198. 2011, Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells, Blood, 117, 2567, 10.1182/blood-2010-07-295238 · DOI · Paper page
  199. 2019, Hematologic malignancies and Li–Fraumeni syndrome, Mol. Case Stud., 5, a003210, 10.1101/mcs.a003210 · DOI
  200. 2016, Acute myeloid leukemia with TP53 germ line mutations, Blood, 128, 2270, 10.1182/blood-2016-08-732610 · DOI

200 of 203 shown

Cited by

See all 16

Metadata

Authors
Liu, Y.-C., Eldomery, M. K., Maciaszek, J. L., & Klco, J. M.
Affiliations
Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA; email: jeffery.klco@stjude.org
Venue
Annual Review of Pathology: Mechanisms of Disease
Published
2025-01-24
Volume
20
Issue
1
Pages
87-114
ISSN
  • 1553-4006
  • 1553-4014
Cited by
16
References
22
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inherited Predispositions to Myeloid Neoplasms: Pathogenesis and Clinical Implications. https://app.cochat.ai/papers/10.1146/annurev-pathmechdis-111523-023420
The paper
Liu, Y.-C., Eldomery, M. K., Maciaszek, J. L., & Klco, J. M. (2025). Inherited Predispositions to Myeloid Neoplasms: Pathogenesis and Clinical Implications. Annual Review of Pathology: Mechanisms of Disease. https://doi.org/10.1146/annurev-pathmechdis-111523-023420

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.